1050results about "Recombinant DNA-technology" patented technology

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications. In some embodiments, the present disclosure provides technologies useful for manufacturing oligonucleotides.

An improved method of treating cancers with engineered T cells is described.

The present invention relates to a novel process for preparing compounds of formula (I) and pharmaceutically acceptable salts thereof which act as ferroportin inhibitors suitable for use as pharmaceuticals in the prevention and / or treatment of diseases caused by a deficiency of hepcidin or of disorders of iron metabolism leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis. JPEG2023533889000140.jpg34103

Provided herein are methods for determining allele-specific telomere length (ATL) and telomere variant repeat (TVR) sequences from long read sequencing data. In some embodiments, the methods include clustering telomere reads together into individual alleles using their adjacent TVR regions from which allele-specific TL can then be determined.

To provide methods of producing hexoses from saccharides by improved enzymatic processes.SOLUTION: Methods of producing hexoses from saccharides by improved enzymatic processes are disclosed herein. The improved processes utilize enzymes with higher activities than those previously reported to convert starch or a starch derivative, cellulose or a cellulose derivative, or sucrose to a glucose 6-phosphate (G6P) intermediate.SELECTED DRAWING: Figure 2

Described herein are serum-free and feeder-free methods and compositions for the tunable differentiation and production of CD4+ (single positive) T cells and CD8+ (single positive) T cells, by adjusting T cell receptor (TCR) stimulation and notch activation (or notch signaling activation, stimulation or inducement). In some other aspects the invention provides a method and in vitro niche and cell culture media that results in enhancing CD4+ (SP) T cell generation, including naive mature CD4+ single positive T cells from double positive (DP) CD4+8+cells or CD8+(SP) T cells by TCR stimulation while having low or no notch signaling activation, stimulation or inducement. In yet other aspects, the invention provides a method, niche and culture media for producing cells derived from CD4+ (SP) T cells, including Treg cells.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

An improved method of treating cancers with engineered T cells is described.

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

The present invention belongs to the field of plant genetics research, and particularly relates to gene functions for increasing plant biomass and seed yield. The present invention discloses the use of a gene that negatively regulates plant biomass and seed yield. This gene is the AT3G28990 gene whose nucleotide sequence is shown in SEQ ID NO: 1. By knocking out the AT3G28990 gene in plants, the biomass and seed yield of plants can be increased. Knocking out the AT3G28990 gene of Arabidopsis thaliana can effectively increase the biomass and yield of plants. This has important reference significance for the breeding of high-yield crops.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and / or therapeutic agent.

The technology described herein is directed to methods of generating CD4+CD8- single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8- single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

To provide a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs.SOLUTION: A composition comprises rhGAA, wherein: 40% to 60% of N-glycan on the rhGAA are complex-type N-glycans; and each rhGAA molecule contains at least one bis-phosphorylated mannose-6-phosphate (bis-M6 P) glycan. A pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable carrier or additive are also provided.SELECTED DRAWING: Figure 1A

This invention provides a system and method for capturing and detecting polynucleotide chains. [Solution] The method may include the step of labeling at least one subsequence within a polynucleotide chain to obtain a labeled polynucleotide chain having at least one label. The method may further include the step of supplying a polymer to the surface of a channel and causing the polymer to physically interact with the surface of the channel. The method may further include the step of supplying a sample containing a labeled polynucleotide chain to the channel, the step of applying an electric field to the labeled polynucleotide chain to promote a physical interaction between the labeled polynucleotide chain and the polymer on the surface of the channel and to capture the labeled polynucleotide chain on the surface of the channel, and the step of detecting at least one label within the labeled polynucleotide chain.

This invention relates to methods and compositions for detecting a polymorphism in a target nucleic acid sequence using isothermal nucleic acid amplification. More specifically, the present invention relates to using recombinase polymerase amplification (RPA) or Nicking and Extension Amplification Reaction (NEAR) to detect single nucleotide polymorphisms in a target nucleic acid sequence.

To provide a method, system, composition, and reagent kit for the diagnosis and differential diagnosis of Alzheimer's disease based on spatial transcriptomics in the human brain hippocampus, which enables differential diagnosis of Alzheimer's disease by detecting one or more of CCK, Neurogranin, and PMP2 carried by plasma-derived extracellular vesicles (EVs). [Solution] This nanoflow cytometry technology focuses on the clinical and research challenges of early and differential diagnosis of cognitive impairments associated with Alzheimer's disease (AD). By utilizing world-leading spatial transcriptomics and single-cell sequencing, along with novel nanoflow cytometry technology, it enables highly sensitive and high-throughput detection of central nervous system-derived EVs (EVs) present in peripheral blood. Offering the advantages of rapid and low-cost detection, and utilizing resources derived from Chinese brains, newly discovered central nervous system brain regions, and cell-specific EV markers, it enables rapid and highly efficient early and differential diagnosis of AD-related cognitive impairments, providing new technological means and methods for precise diagnostic work related to the clinical application and large-scale screening of AD cognitive impairments in clinical settings.

This disclosure provides engineered sesquiterpene synthases, host cells expressing the engineered sesquiterpene synthases, and methods for making alpha-guayene.

To provide a method of inducing the differentiation of pluripotent stem cells into neurons while suppressing the survival of undifferentiated cells in a biological environment that excludes the involvement of unidentified components, without going through the formation process of the germ layer body.SOLUTION: Provided is a method of inducing the differentiation of iPS cells into neurons in a xeno-free culture system without going through the formation process of the germ layer body, the method comprising: a) culturing iPS cells in which a human Neurogenin-2 gene is induced in a laminin-coated vessel; b) transiently inducing expression of the Neurogenin 2 gene to initiate differentiation; and c) culturing the iPS cells that have started differentiation in the laminin-coated vessel and adding, as a development promoting agent for differentiation, at least one of the six types of a small molecule TGFβ family inhibitor, an adenylate cyclase activator, a GSK3 inhibitor, a smoothened agonist, a rock inhibitor, and an indolinone compound.SELECTED DRAWING: Figure 7

It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (iPS cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object. This provides a method for producing a target organ, using an iPS cell, in a living body of a non-human mammal having an abnormality associated with a lack of development of the target organ in a development stage, the target organ produced being derived from a different individual mammal that is an individual different from the non-human mammal.

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Provided are: a genome-edited plant production method by which genome editing can be applied to plants including the family Leguminosae that is difficult to transform, without undergoing processes of tissue culture requiring transformation and time; and a genome-edited plant obtained by said method. The present invention pertains to a genome-edited plant production method and a genome-edited plant obtained by said method, the genome-edited plant production method comprising: providing a cutout in a part of a plant capable of autonomously growing; injecting, to the cutout, an Agrobacterium-containing solution for genome editing; introducing a mutation into the plant without leaving a foreign gene therein; and collecting seeds from the plant, into which the mutation has been introduced, without subjecting the plant to a re-differentiation step, to obtain a genome-edited plant.

The present invention provides a method for producing immobilized cells for producing mannose, and a method for producing mannose, which include the steps of obtaining fermentation liquids of Escherichia coli or Bacillus subtilis in which α-glucan phosphorylase, phosphoglucomutase, glucose phosphate isomerase, mannose 6-phosphate isomerase, and mannose 6-phosphate phosphatase have been expressed by fermentation, and mixing the fermentation liquids to obtain a fermentation mixture.

Disclosed herein are systems, methods, and compositions for bioluminescence-induced catalysis of bioorthogonal labeling chemistry in a proximity-dependent manner. In particular, bioluminescent proteins or complexes, their fluorophore substrates, photocatalysts or photosensitizers, activatable labels, and systems thereof, as well as methods for catalytically activating activatable labels via bioluminescence-induced catalysis are provided herein.

The present invention provides a method and composition for generating basal forebrain cholinergic neurons (BFCNs). [Solution] A highly reproducible protocol for efficiently obtaining BFCNs from pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), provides a method and composition for generating BFCNs from stem cells, particularly BFCNs in which electrophysiological abnormalities associated with one or more mutations in PSEN2 have been repaired, as well as the use of such BFCNs in cell-based therapies for treating Alzheimer's disease. TIFF2026108846000021.tif41148

It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.

To provide a method for suppressing non-specific nucleic acid amplification in an RT-RamDA reaction.SOLUTION: The present invention provides a method for suppressing non-specific nucleic acid amplification that may occur in an RT-RamDA reaction solution by coexisting a template RNA and a chaotropic agent in the RT-RamDA reaction solution. Preferably, the final concentration of the chaotropic agent in the RT-RamDA reaction solution is more than 0 mM and 50 mM or less. The chaotropic agent is preferably at least one selected from the group consisting of guanidinium ion, urea ion, iodide ion, lithium ion, and salts thereof.SELECTED DRAWING: None

Provided are compositions, methods, and systems for DNA pyrimidine-base editing. In some embodiments, provided are engineered thymine-modifying polypeptides or engineered cytosine-modifying polypeptides comprising a variant of a uracil-DNA glycosylate (UNG). In some embodiments, provided are such engineered polypeptides and a DNA recognition domain, which are configured to target a nucleic acid for excision. Also provided herein are nucleic acid encoding the polypeptides described herein, additional components useful for editing, such as sgRNA, kits, medicines, composition, and method of use thereof.